Article

HTA Quarterly Fall 2025 Summary

In this edition, we continue our three-part series on France’s Early Access Program, exploring evolving evidence requirements and their implications for managing clinical and financial uncertainties. We also turn our attention to North America, examining the recent establishment of state-level Prescription Drug Affordability Boards to address high prescription drug prices in the U.S., and how the Canadian Drug Agency incorporates patient perspectives into health technology appraisals, shaping the data used for evaluations.

Subscribe to HTA Quarterly

Article

Changing evidence requirements for France’s Early Access Program (EAP): What could we see in the coming year?

Read article

Article

Unlocking the voice of patients: Are engagement initiatives truly transforming Canadian HTA reviews?

Read article

Article

PDABs: An imperfect solution to a complex issue

Read article

Heard on the street

“Helping other countries strengthen their health technology assessment capabilities, we can simultaneously improve global health outcomes and remove barriers that hinder UK economic growth.”

– Pilar Pinilla-Dominguez, Associate Director of NICE International

Source: Strengthening Health Systems Across the Globe | NICE

HTA by the numbers

The first

products are currently being assessed by the JCA—4 oncology treatments and 2 advanced therapy medicinal products.

Sources:
– Joint Clinical Assessments - European Commission

– List of Ongoing Joint Clinical Assessments - European Commission

Connect with our team

Our team of leading value experts is dedicated to transforming evidence, policy insights, and market intelligence into effective global market access strategies. Let us help you navigate today’s complex healthcare landscape with confidence. Reach out to discover how we can support your goals.

Related resources

Report

FDA programs on the horizon: What biopharma companies need to know

Learn more

Guide

Five strategic shifts to lead pharma through change

Learn more

Article

Changing evidence requirements for France’s Early Access Program (EAP): What could we see in the coming year?

Learn more

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.